setomagpran   Click here for help

GtoPdb Ligand ID: 14677

Synonyms: EP262 | example 30 [WO2023192901] | INCB000262
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Setomagpran (likely company research code EP262, Escient Pharmaceuticals) is a Mas-related G protein-coupled receptor MRGPRX2 antagonist/noncompetitive inverse agonist [2-3]. It inhibits basal receptor activity which confirms its inverse agonist action.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 69.09
Molecular weight 554.32
XLogP 5.1
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1C[C@@H](C[C@@H](C1)NC(=O)C2=CN(CC(F)(F)F)N=C2Cl)NC3=CC(=NC4=CC=C(C=C43)Cl)C(F)(F)F
Isomeric SMILES C1C[C@@H](C[C@@H](C1)NC(=O)C2=CN(N=C2Cl)CC(F)(F)F)NC3=CC(=NC4=C3C=C(C=C4)Cl)C(F)(F)F
InChI InChI=1S/C22H19Cl2F6N5O/c23-11-4-5-16-14(6-11)17(8-18(33-16)22(28,29)30)31-12-2-1-3-13(7-12)32-20(36)15-9-35(34-19(15)24)10-21(25,26)27/h4-6,8-9,12-13H,1-3,7,10H2,(H,31,33)(H,32,36)/t12-,13+/m0/s1
InChI Key DBDJWFSUEOBYFN-QWHCGFSZSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Dehn S, Cooper D, Weyer C, Ferguson B, Srinivasan S, Saint-Cyr Proulx E, Bissonnette R. (2026)
EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study.
Dermatol Ther (Heidelb), [Epub ahead of print]. [PMID:42629547]
2. Lanier M, Boehm M, Huang L, Martinborough E, Sainz M, Selfridge B, Yeager A. (2023)
Quinoline derivatives as modulators of mas-related g-protein receptor x2 and related products.
Patent number: WO2023192901A9. Assignee: Escient Pharmaceuticals Inc. Priority date: 29/03/2023. Publication date: 14/12/2023.
3. Wollam J, Solomon M, Villescaz C, Lanier M, Evans S, Bacon C, Freeman D, Vasquez A, Vest A, Napora J et al.. (2024)
Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists.
J Allergy Clin Immunol, 154 (4): 1033-1043. [PMID:38971540]